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Abstract 
Aims.  Most benign bladder pathologies are associated with an increase of extracellular matrix 
(ECM – fibrosis) and may progress from formation of stiffer matrix to a more compliant 
structure.  The aims were to summarise current knowledge of the origins of bladder fibrosis 
and consequences in bladder function.  
Methods.  A meeting at the International Consultation on Incontinence Research Society 2017 
congress discussed the above aims and considered paradigms to reduce the extent of fibrosis.  
Discussants based their arguments on the basis of their own expertise, supplemented by 
review of the literature through PubMed.  Proposals for future work were derived from the 
discussion 
Results. Altered urodynamic compliance when ECM deposition is increased is mirrored by 
changes in the elastic modulus of isolated tissue, whether compliance is decreased or 
increased. No changes to compliance or fibrosis have been reported after botulinum toxin 
injections.  Several paracrine and autocrine agents increase ECM deposition, the role of TGF- 
was particularly emphasised.  None of these agents has a net long-term effect on detrusor 
contractility and the reduction of contractile performance with increased ECM is due solely to a 
loss of detrusor mass.  Several strategies to reduce fibrosis were described, ranging from 
potential therapeutic roles for vitamin-D or endostatin, manipulation of intracellular pathways 
that mediate myofibroblast differentiation and the potential role of the anti-fibrotic hormone 
relaxin.  An understanding of epigenetic regulation of ECM deposition was also considered. 
Conclusions.  The conclusion that reduced bladder contractile function with increased fibrosis is 
due largely to the replacement of detrusor with ECM offers a way forward for future research 
to consider approaches that will restore bladder function by reducing ECM deposition. 
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Background 
At the International Consultation on Incontinence Research Society (ICI-RS) in Bristol, UK, 2017, 
a panel of clinicians and scientists participated in a think-tank to review the consequences of 
increased fibrosis on bladder function and the identification of potentially useful therapeutic 
pathways to reverse the process. This review is a summary of the discussions and suggests 
directions to future research. 
 
Extracellular matrix and fibrosis.   
The extracellular matrix (ECM) is a non-cellular component of all tissues that provides a 
physical structure for the cellular components but also provides mechanical and chemical 
signals required for tissue growth and differentiation.  It consists of fibrous proteins, such as 
collagens, elastins and fibronectins, and a ground substance of proteoglycans.  Connective 
tissue includes ECM and associated cellular components, such as fibroblasts, and fibrosis refers 
to the excessive formation of connective tissue, say as part of a tissue repair or a reactive 
process. 
 
Collagen is the most abundant ECM fibrous protein; its formation into fibrils provides tensile 
strength and the proteins themselves regulate other functions such as cell adhesion, cell 
migration and development1.  There are numerous subtypes and collagen-I and –III are most 
important in determining biomechanical properties.  Elastin is associated with collagen, which 
permits ECM to recoil after stretch, and fibronectin directs the organisation of ECM and 
mediates cell attachment.  Proteoglycans consist of glycosaminoglycan (GAG) chains linked 
covalently to a protein core2.  Matrices of these hydrophilic molecules are able to withstand 
high compressive forces. 
 
ECM in a compliant tissue is formed of a relaxed network of collagen (type-I and –III), elastin 
and fibronectin embedded in a hydrogel of proteoglycans, secreted from non-activated 
fibroblasts, that can resist tensile as well as compressive forces.  The actual composition is in a 
dynamic state dependent on external forces and cytokines and regulated by fibroblast 
secretion of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs)3. 
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Acute injury or release of cytokines due to physical or chemical stresses initiates fibroblastic 
responses to induce a type of wound-healing response.  Injury itself initiates a fibrin clot and an 
inflammatory cascade characterised by transformation of attracted monocytes to 
macrophages.  These in turn further secrete MMPs, growth factors and cytokines, as well as 
stimulate fibroblast migration and proliferation.  The cascade progresses with the synthesis and 
deposition from fibroblasts of greater amounts of ECM proteins such as collagen type-I and –III, 
fibronectin and GAGs4.  The deposition of large amount of ECM proteins increases local 
mechanical stresses induce the transformation or differentiation into myofibroblasts of cell 
types such fibroblasts, epithelial cells or circulating mesenchymal stem cells (see below).  
Myofibroblasts themselves have a much-increased capacity to synthesise and release ECM 
components, are themselves contractile and have the ability to promote the formation of large 
collagen bundles that together make tissue stiffer5.  Continuation of the precipitating 
conditions can persist, for example in the bladder with increased bladder wall stress due to 
outlet obstruction or inflammation induced by ketamine.  Consequently, continued ECM 
deposition and remodelling remain, increased myofibroblast numbers persist and TIMP 
production is greater than that of MMP to generate a fibrosis, a process possibly mediated by 
secretion of transforming growth factor-1 (TGF-1)6,7. 
 
Bladder pathologies: fibrosis, compliance and bladder wall stiffness.   
An increase of fibrosis is associated with lower urinary tract disorders including: outflow tract 
obstruction8; spinal cord injury9; radiation-induced cystitis10 or paediatric congenital 
anomalies11.  In these pathologies fibrosis is evident in the spaces between muscle bundles and 
when it is more evident within bundles themselves.  In addition, these conditions can often be 
associated with thickening of the lamina propria – between the urothelium and the detrusor – 
where there is also increased deposition of collagens, as well as an increase of interstitial cells 
that include fibroblasts and myofibroblasts12.  
 
Fibrosis might be expected to render the bladder wall stiffer, due to the deposition of greater 
amounts of collagen.  Urodynamic measurements show that a decrease of filling compliance is 
associated with greater fibrosis on both adults13,14 and children15,16 in patients that have 
neurogenic disorders or outflow tract obstruction.  Similar observations have been made in 
some animal models with similar pathologies17,18.  However, decreased compliance is not a 
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ubiquitous phenomenon and several observations in humans and animal pathologies have 
demonstrated a distended, high compliance bladder19-22.  It is not clear whether a low 
compliance phenotype precedes a more distensible, high compliance bladder or whether they 
develop along separate pathways.  However, both are associated with an increased deposition 
of extracellular matrix.  It has been noted by some of the above studies20,21 that high 
compliance bladders are associated with poor contractile performance and it is possible that 
this contributes to the so-called underactive bladder phenotype. 
 
Measurements of bladder compliance have been generally corroborated by more controlled 
biomechanical studies in isolated tissue strips or sheets.  Under these conditions preparations 
are subjected to controlled rapid changes of length (strain) and the change to isometric tension 
(stress) recorded.  With a tissue sample, such as the bladder wall, stress undergoes a partial 
relaxation, due to the relaxation of viscous components, whilst still undergoing the strain 
change.  The elastic modulus, E, of the sample is the ratio of the change to steady-state stress 
for a given proportional change of strain.  A stiffer substance has a higher value of E and may 
be regarded as being less distensible.  This reciprocal relationship between elastic modulus and 
distensibility is reflected in an understanding of the term compliance, C, for a hollow structure 
such as the bladder, whereby C is the ratio of a change of volume, ∆V, for a change of internal 
pressure, ∆P; ie, C=∆V/∆P.  Thus, there should be a reciprocal relationship between stiffness of 
bladder wall strips and the filling compliance of the bladder from where the strips were taken.  
This may be demonstrated, by data compared to control bladders and tissue, with: i) strips of 
low elastic modulus from bladders with high compliance (obstructed fetal sheep19); ii) strips of 
high elastic modulus from bladders with low compliance (exstrophy human bladder11); and iii) 
strips of normal elastic modulus from bladders with normal compliance (a subset of human 
obstructed bladders [A Wagg & CH Fry, unpublished data]). 
 
An unresolved question is why bladder wall stiffness increases or decreases under different 
circumstances and it is unclear if the stiffer bladder represents an earlier stage in the process, 
compared to a late-stage more flaccid bladder.  One observation is that with increased collagen 
deposition, many studies show that the subtype changes from one that is predominantly 
collagen-I to a greater proportion of collagen-III23,24.  Increasing the type-III/type-I ratio of 
isolated collagen fibrils decreases their stiffness by up to ten-fold25. One explanation is that 
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compliance depends on the change of collagen ratio compared to the absolute increase of 
collagen.  Another explanation is a variable deposition of proteoglycans, especially the 
extracellular small leucine-rich proteoglycans such as decorin, as these impart viscous 
properties without having great tensile stiffness26.  An increase of proteoglycan deposition20 
would increase viscous relaxation during strain increases and therefore reduce the steady-state 
elasticity27.  Thus, the biomechanical changes to a stiffer or more compliant direction will 
depend on the ratio of collagen to proteoglycan deposition.  Furthermore, stress-strain 
relationships are not linear across all strains.  A recent study with rats showed that at low strain 
levels the increase of stress is much smaller (a ‘toe’ region of the stress-strain relationship), 
which may be explained by initial re-alignment of collagen fibrils without development of 
significant stress, especially in the lamina propria28.  At greater strains fibrils in the lamina 
propria and detrusor developed stress to demonstrate a more linear stress-strain relationship.  
This same study showed that bladder wall from aged animals showed an attenuated ‘toe’ 
region and thus would increase the overall slope of a stress-strain relationship.  The reasons for 
this variable recruitment of collagen fibrils throughout the bladder wall deserves further study. 
 
Botulinum toxin (BoNT/A) injections and bladder wall fibrosis.   
A potential concern with repeated BoNT/A injections is an increase of fibrosis from the trauma 
of injection itself, or an action of BoNT/A itself or agents in the carriage medium.  Children with 
neurogenic detrusor overactivity or with low compliance bladders did not have a greater ECM 
area after BoNT/A injection; and no inflammation or oedema29.  A similar conclusion was 
reached in adults with idiopathic or neuropathic detrusor overactivity who received mucosal 
injection of BoNT/A; namely no change in suburothelium fibrosis, and where available in the 
detrusor layer, before and four or 16 weeks after BoNT/A injection30.  Direct injection of 
BoNT/A into the wall of a bladder with neuropathic detrusor overactivity also caused no 
increase of fibrosis, compared to untreated bladders31.  These observations are in harmony 
with experiments on rats wheren BoNT/A injections actually decreased fibrosis and reduced 
myofibroblast numbers32. 
 
Fibroblasts, myofibroblasts, connective tissue production and detrusor function.   
The role of fibroblasts and myofibroblasts to produce and secrete structural and adhesive 
proteins as well as the ground substance that comprises ECM has been described above.  It is of 
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value to understand the cellular pathways involved so that pathogenesis of excessive ECM 
deposition can be characterised and strategies developed to slow and reverse the process.  
Moreover, it is important to appreciate that fibroblasts control not just ECM deposition but 
other linked activity including wound healing, angiogenesis and recruitment of immune cells 
and the inflammatory response.  Several paracrine agents promote fibroblast synthetic activity, 
including: platelet-derived growth factor (PDGF), interleukin-6 (IL-6) and eicosanoid 
leukotrienes33.  Conversely, prostaglandin E2 and prostacyclin (PGI2) reduce the fibrotic 
response. 
 
TGF-s are the archetypal cytokines that promote fibrosis and are produced by other tissues 
but also fibroblasts themselves.  They bind to serine/threonine kinase receptors on the cell 
surface that phosphorylate intracellular Smad2/3 transcription factors to induce collagen 
production and fibrocyte-myofibroblast differentiation34.  IL-13, produced mainly by mast cells, 
stimulates TGF-1 production and hence increased collagen production through fibroblast 
proliferation and transformation to myofibroblasts35. An associated pathway is mediated by 
wnt-like signal transduction. wnt is a paradigm signalling protein that regulates cell 
proliferation, differentiation and migration by activation of membrane frizzled receptors - 
members of the G protein-coupled receptor (GPCR) superfamily - and promotes inhibition of 
glycogen synthase kinase 3β.  A canonical intracellular pathway thereafter prevents the 
degradation of the transcription factor -catenin that in turn acts analogously to Smad2/336. 
This pathway has been identified in the bladder37 but its role in the induction and maintenance 
of fibrosis in benign bladder conditions is unclear.  Of interest, other GPCRs, such as the 
angiotensin type-I and the endothelin 1 receptors, regulate myofibroblast differentiation and 
fibrosis.  
 
Fibrosis of the bladder wall is associated with a reduction of detrusor contractile performance. 
One question that arises is whether this is due solely to the replacement of muscle with ECM or 
if it is exacerbated by reduced muscle contractility associated with the array of paracrine and 
autocrine factors produced by activated fibroblasts and myofibroblasts.  This has been 
addressed in three ways using human detrusor from patients with urodynamically normal and 
from obstructed human bladders [Fry CH, Johal N, unpublished data].  Firstly, the isometric 
force of isolated strips in response to a contractile agonist was normalised to the cross-
  7 
sectional proportion of smooth muscle.  In this case the contractile force was directly 
proportional to the cross-sectional area of muscle and identical in the two groups.  Secondly, 
the maximum velocity of shortening of contractile elements in bladder strips was measured 
using a modification of the Hill plot38 – an index of muscle contractility.  In both cohorts the 
maximum velocity of shortening was statistically similar.  Thirdly, intracellular Ca2+ responses to 
contractile agonists such as carbachol, ATP, high-KCl and caffeine were recorded in isolated 
myocytes, data from the two groups were again statistically similar.  Thus, the reduction of 
contractile force measured in detrusor samples from fibrotic bladders was not associated with 
muscle failure, but was due solely to a replacement of muscle with ECM. 
 
Strategies to reduce fibrosis in pathological bladders.  
Several approaches have been developed to reduce the production of ECM by fibroblasts 
and/or limit the differentiation of fibroblasts to myofibroblasts.  For example, the active form 
of vitamin-D (1,25-dihydroxy-vitamin D3) reduces type-I collagen production in hepatic cells39 
and reduced fibrosis in other tissues such as lung parenchyma.  Furthermore, vitamin-D3 
deficiency is associated with liver fibrosis40.  Endostatin is a small peptide derived from the 
carboxy-terminus of collagen type-XVIII and released by fibroblasts.  The carboxy-terminal has 
antifibrotic properties (the amino-terminal inhibits angiogenesis) possibly via the TGF- 
pathway and has been tested in lung and skin tissues41.   
 
Another strategic approach is to limit myofibroblast generation, a contractile phenotype 
characterised by expression of -smooth muscle actin, a greater capacity for collagen secretion 
and a resistance to apoptosis.  Several cells types act as sources for myofibroblast generation 
that include fibroblasts themselves; but also epithelial and endothelial cells; vascular smooth 
muscle cells; pericytes; and circulating blood cells such as monocytes and fibrocytes.  These 
transitions are controlled by several developmental signalling pathways mediated by factors 
such as wnt, Sonic hedgehog and Notch ligands.  Space does not enable detailed description of 
these pathways here but induction of bladder fibrosis from benign conditions offers an 
attractive approach that requires more scrutiny42,43. 
 
Epigenetics studies changes to gene function that do not involve changes to the DNA sequence.  
This suggests that epigenetic modifications do not alter the DNA sequence itself which suggests 
  8 
they are reversible interventions and thus offer useful therapies to reduce fibrosis.  Such 
modifications include histone post-translational modifications and DNA methylation events. For 
example, myofibroblast differentiation stimulated by TGF-β is mediated by histone deacetylase 
4 and offers an attractive target44.  Reduced histone acetylation attenuates the expression of 
cyclo-oxygenase-2, an enzyme that generates antifibrotic prostaglandins45.  
 
There is increasing interest in the role of the hormone relaxin as an agent to reverse fibrosis. 
This peptide hormone is part of the insulin superfamily whose production is increased during 
pregnancy and among other roles relaxes pelvic ligaments, softens the pubic symphysis and has 
a general antifibrotic action.  There are eight peptide members (relaxin-1 to -4 and insulin-like-
peptide-3 to -6) and four receptors (RXFP1 to RXFP4).  Relaxin-2 is best characterized and binds 
to RXFP1, a G-protein coupled receptor that increases intracellular cAMP46.  The final 
intracellular pathways require clarification but relaxin treatment increases MMP expression 
and downregulates TIMP expression.  There is evidence that this involves the inhibition of the 
TGF-/pSmad2-induced increase of myofibroblast differentiation47.   Serelaxin is a 
recombinant form of human relaxin-2 that has been trialled as an antifibrotic agent.  It has 
been successful in human trials concerned with renal dysfunction in cirrhosis48 and shows 
promise for other conditions such as pulmonary fibrosis49.  No trials have been carried out in 
the bladder but a brief report demonstrated that effectiveness of relaxin to reverse fibrosis 
from exposure to X-rays to restore normal cystometric function50. 
 
Conclusions   
An increase of extracellular matrix (ECM) is a feature of bladder wall morphology that 
accompanies many benign lower urinary tract conditions.  One feature is a decrease in bladder 
compliance which is mirrored by an alteration in tissue stiffness.  Collagen deposition generally 
has detrimental consequences on the active and passive contractile properties of the bladder 
wall.  Thus, paradigms to reduce ECM deposition would be therapeutically attractive.  Several 
possibilities exist, that require detailed examination in vitro and in vivo, ranging from the use of 
antifibrotic agents, manipulation of intracellular pathways that mediate altered expression and 
translation of ECM components, through to epigenetic manipulation of the genome. 
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Research questions 
1. Measure the composition of ECM in terms of collagen subtypes and proteoglycans in 
relation to the stress-strain properties of bladder wall tissue. 
2. Characterise the TGF- and wnt-signalling pathways in detrusor and lamina propria layers. 
3. Determine the effectiveness of anti-fibrotic strategies to reduce bladder wall fibrosis. 
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